A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis.
Peginesatide (OMONTYS®) is an erythropoiesis-stimulating agent that was indicated in the United States for the treatment of anemia due to chronic kidney disease in adult patients on dialysis prior to its recent marketing withdrawal by the manufacturer. The objective of this analysis was to develop a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0066422 |
| _version_ | 1818575249503944704 |
|---|---|
| author | Himanshu Naik Max C Tsai Jill Fiedler-Kelly Ping Qiu Majid Vakilynejad |
| author_facet | Himanshu Naik Max C Tsai Jill Fiedler-Kelly Ping Qiu Majid Vakilynejad |
| author_sort | Himanshu Naik |
| collection | DOAJ |
| description | Peginesatide (OMONTYS®) is an erythropoiesis-stimulating agent that was indicated in the United States for the treatment of anemia due to chronic kidney disease in adult patients on dialysis prior to its recent marketing withdrawal by the manufacturer. The objective of this analysis was to develop a population pharmacokinetic and pharmacodynamic model to characterize the time-course of peginesatide plasma and hemoglobin concentrations following intravenous and subcutaneous administration. Plasma samples (n = 2,665) from 672 patients with chronic kidney disease (on or not on dialysis) and hemoglobin samples (n = 18,857) from 517 hemodialysis patients (subset of the 672 patients), were used for pharmacokinetic-pharmacodynamic model development in NONMEM VI. The pharmacokinetic profile of peginesatide was best described by a two-compartment model with first-order absorption and saturable elimination. The relationship between peginesatide and hemoglobin plasma concentrations was best characterized by a modified precursor-dependent lifespan indirect response model. The estimate of maximal stimulatory effect of peginesatide on the endogenous production rate of progenitor cells (Emax) was 0.54. The estimate of peginesatide drug concentration required for 50% of maximal response (EC50) estimates was 0.4 µg/mL. Several significant (P<0.005) covariates affected simulated peginesatide exposure by ≤36%. Based upon ≤0.2 g/dL effects on simulated hemoglobin levels, none were considered clinically relevant. |
| first_indexed | 2024-12-15T00:37:40Z |
| format | Article |
| id | doaj.art-4b69e4dfd05b48daa768fea949805b53 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-15T00:37:40Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-4b69e4dfd05b48daa768fea949805b532022-12-21T22:41:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6642210.1371/journal.pone.0066422A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis.Himanshu NaikMax C TsaiJill Fiedler-KellyPing QiuMajid VakilynejadPeginesatide (OMONTYS®) is an erythropoiesis-stimulating agent that was indicated in the United States for the treatment of anemia due to chronic kidney disease in adult patients on dialysis prior to its recent marketing withdrawal by the manufacturer. The objective of this analysis was to develop a population pharmacokinetic and pharmacodynamic model to characterize the time-course of peginesatide plasma and hemoglobin concentrations following intravenous and subcutaneous administration. Plasma samples (n = 2,665) from 672 patients with chronic kidney disease (on or not on dialysis) and hemoglobin samples (n = 18,857) from 517 hemodialysis patients (subset of the 672 patients), were used for pharmacokinetic-pharmacodynamic model development in NONMEM VI. The pharmacokinetic profile of peginesatide was best described by a two-compartment model with first-order absorption and saturable elimination. The relationship between peginesatide and hemoglobin plasma concentrations was best characterized by a modified precursor-dependent lifespan indirect response model. The estimate of maximal stimulatory effect of peginesatide on the endogenous production rate of progenitor cells (Emax) was 0.54. The estimate of peginesatide drug concentration required for 50% of maximal response (EC50) estimates was 0.4 µg/mL. Several significant (P<0.005) covariates affected simulated peginesatide exposure by ≤36%. Based upon ≤0.2 g/dL effects on simulated hemoglobin levels, none were considered clinically relevant.https://doi.org/10.1371/journal.pone.0066422 |
| spellingShingle | Himanshu Naik Max C Tsai Jill Fiedler-Kelly Ping Qiu Majid Vakilynejad A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. PLoS ONE |
| title | A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. |
| title_full | A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. |
| title_fullStr | A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. |
| title_full_unstemmed | A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. |
| title_short | A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. |
| title_sort | population pharmacokinetic and pharmacodynamic analysis of peginesatide in patients with chronic kidney disease on dialysis |
| url | https://doi.org/10.1371/journal.pone.0066422 |
| work_keys_str_mv | AT himanshunaik apopulationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT maxctsai apopulationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT jillfiedlerkelly apopulationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT pingqiu apopulationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT majidvakilynejad apopulationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT himanshunaik populationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT maxctsai populationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT jillfiedlerkelly populationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT pingqiu populationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis AT majidvakilynejad populationpharmacokineticandpharmacodynamicanalysisofpeginesatideinpatientswithchronickidneydiseaseondialysis |